Oncologic Outcomes of Patients With Resected T3N0M0 Non-small Cell Lung Cancer

被引:2
|
作者
Marques, Edouard [1 ]
Kennedy, Kevin F. [2 ]
Giroux, Dorothy J. [2 ]
Cilento, Vanessa B. [2 ]
Nishimura, Katherine K. [2 ]
Fang, Wentao [3 ]
Figueroa, Paula Ugalde [4 ,5 ]
机构
[1] Laval Univ, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
[2] Canc Res & Biostatist, Seattle, WA USA
[3] Jiaotong Univ, Med Sch, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[4] Harvard Univ, Brigham & Womens Hosp, Div Thorac & Cardiac Surg, Boston, MA USA
[5] Brigham & Womens Hosp, Div Thorac & Cardiac Surg, 75 Francis St, Boston, MA 02115 USA
关键词
FORTHCOMING 8TH EDITION; ADJUVANT CHEMOTHERAPY; SURGICAL-TREATMENT; CHEST-WALL; SURVIVAL; PROPOSALS; NODULES;
D O I
10.1053/j.semtcvs.2022.08.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the eighth edition TNM staging, the T3N0M0 category represents a heterogeneous group of non-small cell lung cancers (NSCLC). This study aims to compare the oncologic outcomes associated with individual T3 features. We performed a single-institution, retrospective analysis of 280 consecutive patients with pT3N0M0 NSCLC. Multivariate regression models were used to estimate associations of clinical factors with oncologic outcomes. The patients were grouped according to their T3 features into 4 prognostic groups: chest wall infiltration (CWI-PG), largest diameter >5 cm and ≤7 cm (Size-PG), presence of a satellite nodule (SN-PG), and all other T3 features. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier and Cox proportional hazard analyses. Tumors were most often classified as T3N0M0 by size (156 patients, 55.7%), and the highest rate of incomplete resection occurred in patients with CWI (n = 7, 25.9%). In multivariate analysis, CWI (hazard ratio [HR] 2.45, 95% confidence interval [CI] 1.36, 4.44), incomplete resection (HR 3.01, 95% CI 1.29, 7.05), and age >65 (HR 1.6; 95% CI 1.08, 2.38) were independently associated with worse OS, and female sex was associated with better OS (HR 0.6, 95% CI 0.42, 0.87). The CWI-PG had poorer OS when compared with each of the other prognostic groups (P < 0.05), and the Size-PG had inferior OS when compared with the SN-PG (P = 0.039). This single-center study demonstrated significant differences in OS and PFS between patients with different T3 classifying features and suggest that further subdivision of the T3 category should be considered. © 2022 Elsevier Inc.
引用
收藏
页码:796 / 804
页数:9
相关论文
共 50 条
  • [1] Oncologic Outcomes of Patients with Resected T3N0M0 Non-small Cell Lung Cancer
    Marques, E.
    Kennedy, K.
    Nishimura, K.
    Giroux, D.
    Cilento, V.
    Fang, W.
    Ugalde, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S866 - S867
  • [2] Stereotactic ablative radiotherapy ( SABR) for non-small cell lung cancer (NSCLC): analysis of T3N0M0 patients
    Pickles, R.
    Atherton, P.
    Turnbull, H.
    Burns, A.
    Iqbal, M. S.
    [J]. LUNG CANCER, 2020, 139 : S31 - S31
  • [3] Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures
    Parsons, M.
    Johnson, S.
    Tao, R.
    Hitchcock, Y.
    Puri, S.
    Akerley, W.
    Kokeny, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1040 - S1040
  • [4] Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer
    Kodama, Ken
    Higashiyama, Masahiko
    Okami, Jiro
    Tokunaga, Toshiteru
    Imamura, Fumio
    Nakayama, Tomio
    Inoue, Atsuo
    Kuriyama, Keiko
    [J]. ANNALS OF THORACIC SURGERY, 2016, 101 (02): : 504 - 511
  • [5] Segmentectomy for c-T1N0M0 non-small cell lung cancer
    Hiroaki Nomori
    [J]. Surgery Today, 2014, 44 : 812 - 819
  • [6] Segmentectomy for c-T1N0M0 non-small cell lung cancer
    Nomori, Hiroaki
    [J]. SURGERY TODAY, 2014, 44 (05) : 812 - 819
  • [7] Adjuvant chemotherapy for patients with T2N0M0 non-small cell lung cancer.
    Morgensztern, Daniel
    Waqar, Saiama Naheed
    Patel, Aalok
    Devarakonda, Siddhartha
    Waqar, Sadaf Huma
    Gao, Feng
    Robinson, Cliff Grant
    Bradley, Jeffrey D.
    Baggstrom, Maria Quintos
    Govindan, Ramaswamy
    Puri, Varun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx
    Ko, Huaising C.
    Harari, Paul M.
    Chen, Shuai
    Wieland, Aaron M.
    Yu, Menggang
    Baschnagel, Andrew M.
    Kimple, Randall J.
    Witek, Matthew E.
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2017, 143 (11) : 1126 - 1133
  • [9] Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx
    D'Ascanio, Luca
    Piazza, Fabio
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2018, 144 (06) : 542 - 543
  • [10] Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer
    Eriguchi, Takahisa
    Takeda, Atsuya
    Sanuki, Naoko
    Nishimura, Shuichi
    Takagawa, Yoshiaki
    Enomoto, Tatsuji
    Saeki, Noriyuki
    Yashiro, Kae
    Mizuno, Tomikazu
    Aoki, Yousuke
    Oku, Yohei
    Yokosuka, Tetsuya
    Shigematsu, Naoyuki
    [J]. JOURNAL OF RADIATION RESEARCH, 2016, 57 (03) : 265 - 272